NASDAQ:ALPS • KYG0231P1081
The current stock price of ALPS is 0.9 USD. In the past month the price decreased by -10%.
ChartMill assigns a technical rating of 2 / 10 to ALPS.
ChartMill assigns a fundamental rating of 1 / 10 to ALPS. ALPS has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ALPS reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS decreased by -216.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.77% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
ALPS GROUP INC
Unit E-18-01 & E-18-02, Level 18,, Icon Tower (East), No.1,Jalan 1/68F,
KUALA LUMPUR WILAYAH PERSEKUTUAN MY
Employees: 0
Phone: 60321631113
Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
The current stock price of ALPS is 0.9 USD. The price decreased by -0.19% in the last trading session.
ALPS does not pay a dividend.
ALPS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
ALPS GROUP INC (ALPS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
ALPS GROUP INC (ALPS) has a market capitalization of 155.20M USD. This makes ALPS a Micro Cap stock.